Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

doi:10.1158/0008-5472.CAN-10-3001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Cancer research - 1 Dec 2010

Payton Marc, Bush Tammy L, Chung Grace, Ziegler Beth, Eden Patrick, McElroy Patricia, Ross Sandra, Cee Victor J, Deak Holly L, Hodous Brian L, Nguyen Hanh Nho, Olivieri Philip R, Romero Karina, Schenkel Laurie B, Bak Annette, Stanton Mary, Dussault Isabelle, Patel Vinod F, Geuns-Meyer Stephanie, Radinsky Robert, Kendall Richard L

Abstract excerpt

In mammalian cells, the aurora kinases (aurora-A, -B, and -C) play essential roles in regulating cell division. The expression of aurora-A and -B is elevated in a variety of human cancers and is associated with high proliferation rates and poor prognosis, making them attractive targets for anticancer therapy. AMG 900 is an orally bioavailable, potent, and highly selective pan-aurora kinase inhibitor that is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aurora Kinase B

Share to Aurora Kinases

Share to Drug Evaluation, Preclinical

Share to HCT116 Cells

Share to Organophosphates

Share to Paclitaxel

Share to Phthalazines

Source

Open in PubMed

Identifiers

PMID: 20935223
DOI: 10.1158/0008-5472.CAN-10-3001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.PMID 20935223Read ↗

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase InhibitorSemantic proximity Read ↗

Aurora kinase inhibitors as anti-cancer therapySemantic proximity Read ↗

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.Semantic proximity Read ↗

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read ↗

Aurora Kinases as Anticancer Drug TargetsSemantic proximity Read ↗

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacySemantic proximity Read ↗

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft modelsSemantic proximity Read ↗

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsSemantic proximity Read ↗

Aurora-A Kinase as a Promising Therapeutic Target in CancerSemantic proximity Read ↗

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?Semantic proximity Read ↗

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeuticsSemantic proximity Read ↗

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.